Patents by Inventor Xiawei Jiang

Xiawei Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TABLET COMPRISING MODOFLANER AS AN ACTIVE COMPONENT
    Publication number: 20240025855
    Abstract: The present invention relates to a crystalline modification of Modoflaner 6-fluoro-N-(3-(2-iodo-4-(perfluoropropan-2-yl)-6-(trifluoromethyl)phenylcarbamoyl)-2-fluorophenyl)nicotinamide of formula (I):
    Type: Application
    Filed: November 16, 2021
    Publication date: January 25, 2024
    Inventors: Anja FÖRSTER, Fabian SIMONS, Li ZHANG, Xiawei JIANG, Britta OLENIK, Sylvia DWORACEK
  • CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF
    Publication number: 20230382899
    Abstract: Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.
    Type: Application
    Filed: October 13, 2021
    Publication date: November 30, 2023
    Inventors: Wenge Zhong, Wei Guo, Zheng Jane Li, Xiawei Jiang, Pengyuan Chen
  • Crystalline forms of lasmiditan, preparation methods, pharmaceutical compositions and uses thereof
    Patent number: 10669256
    Abstract: The present invention relates to the crystalline forms of a 5-HT1F receptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the present invention have advantages in crystallinity, hygroscopicity, morphology, crystal form stability, and chemical stability as compared with the known forms of lasmiditan and lasmiditan hydrochloride. The present invention also relates to processes for the preparation of the crystalline forms of lasmiditan and lasmiditan hydrochloride, pharmaceutical compositions thereof and their use in treating and/or preventing a patient's migraine and other diseases or conditions associated with 5-HT1F receptor dysfunction.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 2, 2020
    Assignee: Hangzhou SoliPharma Co., Ltd.
    Inventors: Xiaohong Sheng, Xiaoxia Sheng, Xiawei Jiang
  • CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
    Publication number: 20190233393
    Abstract: The present invention relates to the crystalline forms of a 5-HT1F receptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the present invention have advantages in crystallinity, hygroscopicity, morphology, crystal form stability, and chemical stability as compared with the known forms of lasmiditan and lasmiditan hydrochloride. The present invention also relates to processes for the preparation of the crystalline forms of lasmiditan and lasmiditan hydrochloride, pharmaceutical compositions thereof and their use in treating and/or preventing a patient's migraine and other diseases or conditions associated with 5-HT1F receptor dysfunction.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 1, 2019
    Applicant: Solipharma LLC
    Inventors: Xiaohong SHENG, Xiaoxia SHENG, Xiawei JIANG